jRCT2080224848已完成3 期
An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 505
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Open-label, Multicenter study
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1)At visit1(-4 weeks), Subject must be fully informed about the study and must obtain written informed consent from the subject himself.
- •(2)At Visit2(0 week), Subjects must have completed the previous study (TS152-3000-JA or TS152-3001-JA) ,and must have completed all evaluations required at the follow-up visit.
排除标准
- •Subjects who had serious adverse drug reactions in the previous study.
- •At Visit1(-4 weeks) or Visit2 (0 week), Subjects who have not recovered from clinically important adverse events.
结局指标
主要结局
-
safety efficacy ACR20 adverse event,Side effects etc.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
An Extension Study of TS-152 in Subjects with Rheumatoid ArthritisRheumatoid ArthritisJPRN-jRCT2080224848Taisho Pharmaceutical Co.Ltd505
已完成
2 期
ate Phase II Study of TS-142 in Patients with InsomniaInsomnia DisorderJPRN-jRCT2080225269Taisho Pharmaceutical Co., Ltd.160
已完成
2 期
Late Phase II Study of TS-142 in Patients with InsomniajRCT2080225269Taisho Pharmaceutical Co., Ltd.160
已完成
2 期
Early Phase II Clinical Study of TS-142 in Patients with InsomniaInsomniaJPRN-jRCT2080223515Taisho Pharmaceutical co., LTD32
已完成
不适用
A pharmacokinetic study of TS-142 in patients with hepatic impairmentInsomniajRCT2031220463Taisho Pharmaceutical Co., LTD.24